Advertisement
Research Article| Volume 17, ISSUE 5, P327-329, September 1995

Studies on cerebrospinal fluid kynurenic acid concentrations in epileptic children

DOI:https://doi.org/10.1016/0387-7604(95)00065-J
Studies on cerebrospinal fluid kynurenic acid concentrations in epileptic children
Previous ArticleFrequency of the Prader-Willi syndrome in the San-in district, Japan
Next ArticleTreatment of electrical status epilepticus by short diazepam (DZP) cycles after DZP rectal bolus test
      This paper is only available as a PDF. To read, Please Download here.

      Abstract

      Kynurenic acid (KYA), the only known endogenous antagonist of the excitatory amino acids, is a metabolite of kynurenine. In the present study the levels of KYA were measured in the cerebrospinal fluid (CSF) of epileptic children and age-matched controls to investigate the relationship between various forms of epilepsy and KYA levels. CSF samples from four patients with West syndrome (WS), four patients with epilepsy with grand mal seizures on awakening (EGSA), and four patients with childhood epilepsy with occipital paroxysms (CEOP) were collected by lumbar puncture before treatment. The concentration of CSF KYA was analyzed by HPLC with electrochemical detection and compared with those of age-matched controls. The levels of CSF KYA were significantly lower (P < 0.05) in patients with WS compared with controls. The levels of CSF KYA in patients with EGSA and with CEOP did not differ significantly from control levels. These results suggest that the presence of seizures in WS is associated with altered kynurenine metabolism. The possibility that seizures in WS may be related to decreased production of KYA is discussed.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Brain and Development
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      Reference

        • Heyes M.P.
        • Quearry B.J.
        Quantification of kynurenic acid in cerebrospinal fluid: Effects of systemic and centrall-kynurenine administration.
        J Chromatogr Biomed. 1990; 530: 108-115
        • Beal M.F.
        • Natson W.R.
        • Storey E.
        • et al.
        Kynurenic acid concentrations are reduced in Huntington's cerebral cortex.
        J Neurol Sci. 1992; 108: 80-87
        • Connick J.H.
        • Carla V.
        • Moroni F.
        • Stone T.W.
        Increase in kynurenic acid in Huntington's disease motor cortex.
        J Neurochem. 1989; 52: 985-987
        • Swartz K.J.
        • Matson W.R.
        • MacGarvey U.
        • Ryan E.A.
        • Beal M.F.
        Measurement of kynurenic acid in mammalian brain extracts and cerebrospinal fluid by high-performance liquid chromatography with fluorometric and coulometric electrode array detection.
        Anal Biochem. 1990; 185: 363-376
        • Moroni F.
        • Lombardi G.
        • Robitaille Y.
        • Etienne P.
        Senile dementia and Alzheimer's disease: lack of changes of the cortical content of quinolinic acid.
        Neurobiol Aging. 1986; 7: 249-253
        • Stone T.W.
        • Connick J.H.
        Quinolinic acid and other kynurenines in the central nervous system.
        Neuroscience. 1985; 15: 597-617
        • Swartz K.J.
        • During M.J.
        • Freese A.
        • Beal M.F.
        Cerebral synthesis and release of kynurenic acid: an endogenous antagonist of excitatory amino acid receptors.
        J Neurochem. 1990; 10: 2965-2973
        • Saito K.
        • Nowak Jr, T.S.
        • Markey S.P.
        • Heyes M.P.
        Mechanism of delayed increases in kynurenine pathway metabolism in damaged brain regions following transient cerebral ischemia.
        J Neurochem. 1993; 60: 180-192
        • Parkins M.N.
        • Stone T.W.
        An iontophoretic investigation of the actions of convulsant kynurenines and their interaction with the endogenous excitant quinolinic acid.
        Brain Res. 1982; 247: 184-187
        • Freese A.
        • Swartz K.J.
        • During M.J.
        • Martin J.B.
        Kynurenine metabolites of tryptophan: Implications for neurologic diseases.
        Neurology. 1990; 40: 691-695
        • Yamamoto H.
        Studies on CSF tryptophan metabolism in infantile spasms.
        Pediatr Neurol. 1991; 7: 411-414
        • Beal M.F.
        • Kowall N.W.
        • Edison D.W.
        • Mazurek M.F.
        • Swartz K.J.
        • Martin J.B.
        Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid.
        Nature. 1986; 321: 168-171
        • Danysz W.
        • Fadda E.
        • Wroblewski J.T.
        • Costa E.
        Kynurenate and 2-amino-5-phosphonovalerate interact with multiple binding sites of the N-methyl-D-aspartate glutamate receptor domain.
        Neurosci Lett. 1989; 96: 340-344
        • Lapin I.P.
        Kynurenines and seizures.
        Epilepsia. 1981; 22: 257-265
        • Schwarcz R.
        • Whetsell W.O.
        • Mangano R.M.
        Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain.
        Science. 1983; 219: 316-318
        • Lloyd K.G.
        • Bossi L.
        • Morselli P.L.
        • Munari C.
        • Rougier M.
        • Loiseau H.
        Alterations of GABA-mediated synaptic transmission in human epilepsy.
        in: 2nd edn. Advances in neurology. Vol. 44. Raven Press, New York1986: 1033-1044
        • Young S.N.
        • Joseph M.H.
        • Gauthier S.
        Studies on kynurenine in human cerebrospinal fluid: lowered levels in epilepsy.
        J. Neural Transm. 1983; 58: 193-204
        • Habel A.
        • Yates C.M.
        • McQueen J.K.
        • Blackwood D.
        • Elton R.A.
        Homovanillic acid and 5-hydroxyindoleacetic acid in lumbar cerebrospinal fluid in children with afebrile and febrile convulsions.
        Neurology. 1981; 31: 488-491
        • Wood J.H.
        Neurochemical analysis of cerebrospinal fluid.
        Neurology. 1980; 30: 645-651
        • Langlais P.J.
        • Wardlow M.L.
        • Yamamoto H.
        Changes in CSF neurotransmitters in infantile spasms.
        Pediatr Neurol. 1991; 7: 440-445

      Article info

      Publication history

      Accepted: May 5, 1995
      Received: March 10, 1994

      Identification

      DOI: https://doi.org/10.1016/0387-7604(95)00065-J

      Copyright

      © 1995 Elsevier Science B.V. All rights reserved. Published by Elsevier Inc.

      ScienceDirect

      Access this article on ScienceDirect

      The content on this site is intended for healthcare professionals.


      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties.


      RELX